Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

NCT04385368 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Durvalumab + SoC chemotherapy
OTHER: Placebo + SoC chemotherapy

Sponsor

AstraZeneca